(18)F-FDG PET in sarcoma treatment response imaging

di Eary, Janet F, Hawkins, Douglas S, Rodler, Eve T, Conrad, Ernest U
Pubblicazione 2011

Immune-Based Therapies for Sarcoma

di Pollack, Seth M., Loggers, Elizabeth T., Rodler, Eve T., Yee, Cassian, Jones, Robin L.
Pubblicazione 2011

Systemic therapy in primary angiosarcoma of the spleen

di Ferreira, Bruna Pellini, Rodler, Eve T., Loggers, Elizabeth T., Pollack, Seth M., Jones, Robin L.
Pubblicazione 2012

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma

di Jones, Robin L., Katz, Daniela, Loggers, Elizabeth T., Davidson, Darin, Rodler, Eve T., Pollack, Seth M.
Pubblicato in Med Oncol (2017)

NYESO-1/LAGE-1s and PRAME Are Targets for Antigen Specific T Cells in Chondrosarcoma following Treatment with 5-Aza-2-Deoxycitabine

di Pollack, Seth M., Li, Yonqing, Blaisdell, Megan J., Farrar, Erik A., Chou, Jeffrey, Hoch, Benjamin L., Loggers, Elizabeth T., Rodler, Eve, Eary, Janet F., Conrad, Ernest U., Jones, Robin L., Yee, Cassian
Pubblicazione 2012

Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients

di Kurland, Brenda F, Gadi, Vijayakrishna K, Specht, Jennifer M, Allison, Kimberly H, Livingston, Robert B, Rodler, Eve T, Peterson, Lanell M, Schubert, Erin K, Chai, Xiaoyu, Mankoff, David A, Linden, Hannah M
Pubblicazione 2012

NY-ESO-1 is a Ubiquitous Immunotherapeutic Target Antigen for Patients with Myxoid/ Round Cell Liposarcoma

di Pollack, Seth M., Jungbluth, Achim A., Hoch, Benjamin L., Farrar, Erik A., Bleakley, Marie, Schneider, David J., Loggers, Elizabeth T., Rodler, Eve, Eary, Janet F., Conrad, Ernest U., Jones, Robin L., Yee, Cassian
Pubblicazione 2012

Phase I Trial of Preoperative Chemoradiation Plus Sorafenib for High Risk Extremity Soft Tissue Sarcomas with Dynamic Contrast-Enhanced MRI Correlates

di Meyer, Janelle M., Perlewitz, Kelly S., Hayden, James B., Doung, Yee-Cheen, Hung, Arthur Y., Vetto, John T., Pommier, Rodney F., Mansoor, Atiya, Beckett, Brooke R., Tudorica, Alina, Mori, Motomi, Holtorf, Megan L., Afzal, Aneela, Woodward, William J., Rodler, Eve T., Jones, Robin L., Huang, Wei, Ryan, Christopher W.
Pubblicazione 2013

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

di Rodler, Eve T., Kurland, Brenda F., Griffin, Melissa, Gralow, Julie R., Porter, Peggy, Yeh, Rosa F., Gadi, Vijayakrishna K., Guenthoer, Jamie, Beumer, Jan H., Korde, Larissa, Strychor, Sandra, Kiesel, Brian F., Linden, Hannah M., Thompson, John A., Swisher, Elizabeth, Chai, Xiaoyu, Shepherd, Stacie, Giranda, Vincent, Specht, Jennifer M.
Pubblicato in Clin Cancer Res (2016)

Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung

di Baird, Kristin, Glod, John, Steinberg, Seth M., Reinke, Denise, Pressey, Joseph G., Mascarenhas, Leo, Federman, Noah, Marina, Neyssa, Chawla, Sant, Lagmay, Joanne P., Goldberg, John, Milhem, Mohammed, Loeb, David M., Butrynski, James E., Turpin, Brian, Staddon, Arthur, Spunt, Sheri L., Jones, Robin L., Rodler, Eve T., Schuetze, Scott M., Okuno, Scott H., Helman, Lee
Pubblicato in Sarcoma (2020)